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The persistence of HIV-1 in virally suppressed infected individuals on highly active antiretroviral therapy 
(HAART) remains a major therapeutic problem. The use of cytokines has been envisioned as an additional 
therapeutic strategy to stimulate latent proviruses in these individuals. Immune activation therapy using IL-2 
has shown some promise. In the present study, we found that IL-7 was significantly more effective at enhanc-
ing HIV-1 proviral reactivation than either IL-2 alone or IL-2 combined with phytohemagglutinin (PHA) in 
CD8-depleted PBMCs. IL-7 also showed a positive trend for inducing proviral reactivation from resting CD4+ 
T lymphocytes from HIV-1–infected patients on suppressive HAART. Moreover, the phylogenetic analyses 
of viral envelope gp120 genes from induced viruses indicated that distinct proviral quasispecies had been 
activated by IL-7, as compared with those activated by the PHA/IL-2 treatment. These studies thus demon-
strate that different activators of proviral latency may perturb and potentially deplete only selected, specific 
portions of the proviral archive in virally suppressed individuals. The known immunomodulatory effects of 
IL-7 could be combined with its ability to stimulate HIV-1 replication from resting CD4+ T lymphocytes, in 
addition to other moieties, to potentially deplete HIV-1 reservoirs and lead to the rational design of immune-
antiretroviral approaches.
Introduction
Highly active antiretroviral therapy (HAART) has dramatically 
altered the HIV-1 pandemic, at least in the developed world. Most 
patients treated with HAART maintain clinically undetectable plas-
ma viral loads with concomitant dramatic decreases in mortality 
and morbidity. However, persistently infected resting CD4+ T lym-
phocytes have been demonstrated in the peripheral blood of HIV-1–
infected individuals even after treatment effectively suppressed most 
productive viral infection (1). It has been estimated that most HIV-1– 
infected individuals would require complete suppression of viral 
replication for many decades on current HAART regimens to pos-
sibly reach viral eradication (1). Therefore, new treatment strategies 
designed to purge the pool of latently infected cells are required.
Cytokine treatment has been proposed not only as an immune-
adjunctive therapy to HAART, but also to activate latently 
infected CD4+ T lymphocytes and increase the turnover rate 
of the latent viral reservoir to promote viral clearance. Several 
cytokines, including IL-2, IL-7, and IL-15, which share a common 
γ chain, might have putative roles in improving control of HIV-1 
infection; of these, IL-2 is the best characterized (2–4). Although 
recombinant human IL-2 (rhIL-2) plus HAART produced signifi-
cant CD4+ T lymphocyte expansion without an increase in viral 
load (5–8), the effects of this combination on purging viral reser-
voirs is somewhat unclear (2, 3).
IL-7 is a nonredundant cytokine essential for thymopoiesis, 
which is produced by a number of cell types including stromal 
cells (9), normal and malignant B cells (10), thymic epithelial cells 
(11), intestinal epithelial cells (12), BM-derived fibroblast-like cells 
(13), keratinocytes, and dendritic cells (14). IL-7 has pleiotropic 
effects on T cell homeostasis, such as enhancement of mature T 
cell survival (15–17), expansion of both peripheral CD4+ and CD8+ 
T cells in T lymphocyte–depleted hosts (18), and mobilization of 
hematopoietic stem cells from the bone marrow to the peripheral 
circulation (19). Importantly, IL-7 enhances both HIV-1–specific 
CD8+ cytotoxic cellular activity of humans in vitro (20), as well as 
CD4+ T helper cell–dependent humoral responses and cytotoxic 
CD8+ T cell activity in mice immunized with HIV-1 envelope pro-
tein (21). Furthermore, Kaech et al. (22) demonstrated that, after 
a viral infection, a small population of effector CD8+ T cells had 
increased expression of the IL-7 receptor α. These cells are the 
precursors of the memory CD8+ T cell pool that confers protec-
tive immunity, and their survival was shown to depend on IL-7. 
Napolitano et al. (23) reported that patients with AIDS have high-
er plasma levels of IL-7 than do other HIV-1–infected subjects. IL-7 
levels were inversely correlated with CD4+ T lymphocyte loss and 
directly correlated with plasma HIV-1 viral load. Moreover, Llano 
et al. (24), using the same IL-7 detection kit, demonstrated that 
higher IL-7 plasma levels occur in HIV-1–infected individuals than 
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in healthy donors (9.4 ± 5.7 pg/ml and 3.6 ± 3.05 pg/ml, respective-
ly). Importantly, when HIV-1–seropositive subjects were grouped 
by CD4+ T cell count — less than 200, 200–500, or greater than 
500 — higher values of plasma IL-7 were detected as compared 
with healthy donors (12.26 ± 5.9, 6.67 ± 4.1, and 5.69 ± 2.7 pg/ml, 
respectively) (24). This probably represents a homeostatic response 
to lymphopenia, since the high levels of IL-7 decrease when the 
CD4+ T cell count increases after a HAART regimen is initiated. 
The authors hypothesized that IL-7 might play an important role 
in HIV-1 disease progression (23).
Of note, IL-7 was shown to be able to induce HIV-1 replication 
in vitro from PBMCs of HIV-1–infected individuals who were not 
treated with HAART (25–27), and to increase the expression of 
HIV-1 Tat mRNA in CD8-depleted PBMCs from chronically HIV-1– 
infected patients (25). Moreover, recent in vitro studies indicate 
that IL-7 has minimal effects on T cell phenotype, while inducing 
substantial expression of latent HIV-1 (28–30), which suggests that 
IL-7 might be used as an additive therapy to HAART, not only for 
its immunological effects but also to purge HIV-1–latent reservoirs. 
IL-2 has already been used in a few clinical trials in association with 
HAART, either alone or in combination with OKT 3 (2–4). Howev-
er, whether or not the addition of these immunostimulatory thera-
pies was able to induce significant expression from a true HIV-1 
latent reservoir is controversial. Distinct cytokines play critical roles 
in the regulation of T cell homeostasis and thus they may be ben-
eficial in addition to HAART by virtue of improving the impaired 
immune response. Furthermore, these cytokines could induce the 
replication of different HIV-1 viral strains or archives out of provi-
ral latency. This hypothesis prompted us to assess IL-7 as a thera-
peutic agent in inducing activation of latent HIV-1, to investigate 
its action on quiescent human T lymphocytes in infected patients 
on HAART, and to examine further the molecular and virological 
characteristics of the viruses induced by both IL-7 and IL-2.
New clinical approaches, such as stimulation therapy (or more 
precisely, immune-activation therapy), are now being investigated to 
try to achieve long-term remission or viral eradication. In fact, it has 
been speculated that this strategy aims to increase the turnover of 
latent viral reservoirs through acti-
vation of quiescent infected cells, 
promoting cell death and accel-
erating viral clearance, especially 
when combined with intensifica-
tion of antiretroviral therapy (4).
We demonstrated that IL-7 
was significantly more eff i-
cient than either IL-2 alone or 
even IL-2 in combination with 
phytohemagglutinin (PHA) in 
stimulating HIV-1 replication 
from CD8+ T cell/monocyte–
depleted PBMCs. We also found 
that IL-7 showed a positive trend 
for inducing proviral reactivation 
from resting CD4+ T lymphocytes 
from HIV-1–infected patients 
on suppressive HAART. More-
over, different viral isolates were 
induced by IL-7 and PHA/IL-2, 
which strengthens the hypothesis 
that combination therapy may be 
more efficacious not only for the immunomodulatory effects but 
also to effectively stimulate different latent HIV-1 viral species.
Results
IL-7 promotes HIV-1 replication more efficiently than PHA/IL-2 from 
patients’ PBMCs and resting CD4+ T lymphocytes. The ability of differ-
ent cell activators to induce the expression of persistent HIV-1 was 
evaluated on specific cell populations from 14 well-characterized 
patients on virally suppressive HAART. All the patients involved 
in this study received a stable HAART regimen for over a year, with 
plasma viral RNA levels below 50 copies/ml (Table 1).
As shown in Table 2, a total of 18 paired PBMC coculture reac-
tions and 11 paired resting CD4+ T lymphocyte (CD4+, CD25–/
HLA-DR–) cocultures were treated with IL-7 and PHA/IL-2 in par-
allel. Viral outgrowth was detected in 10 out of 18 (56%) PBMC 
cocultures treated with IL-7, whereas viral outgrowth was detect-
ed in only 4 out of 18 (22%) of those stimulated by PHA/IL-2 
(χ2 = 4.208, P < 0.05). Of note, the 4 patients’ cocultures that were 
positive for HIV-1 outgrowth with PHA/IL-2 were also positive for 
IL-7. However, unlike with IL-7, no viral outgrowth was detected 
from patients’ PBMC cocultures (5 cultures) when IL-2 was used 
alone, without combining with PHA.
When pure resting CD4+ T cells were stimulated with IL-7 or PHA/
IL-2, HIV-1 replication was induced in 5 out of 11 (45.5%) IL-7– 
treated cultures and in 3 out of 11 (27.3%) of those stimulated with 
PHA/IL-2. Two additional IL-7–treated resting CD4+ T lymphocyte 
cocultures were compared with unstimulated cultures and with 
cultures stimulated with IL-2 alone. IL-7 induced HIV-1 replica-
tion in 2 resting CD4+ T cell cocultures, while both unstimulated 
and IL-2–treated cultures remained negative until the end of the 
study. The average first appearance of viral production occurred 
at 3.5 weeks of culture. IL-7–induced viral outgrowth (4.1 weeks 
on average) required 2 weeks longer than outgrowth induced by 
PHA/IL-2 (2 weeks on average). However, both IL-7 and PHA/IL-2 
yielded comparable levels of virus.
In summary, these results indicate that IL-7 is more effective 
than PHA/IL-2 or IL-2 alone in inducing the expression of persis-
Table 1
Clinical characteristics of the patients in this study
Patient  Antiviral  Time period of plasma  CD4+ T lymphocyte Initial plasma HIV-1 
no. therapy viral RNA below   counts  RNA (copies/ml)
  50 copies/ml (mo) (cells/mm3) prior to therapy
1 D4T/3TC/efavirenz 63 548 677,000
2 AZT/3TC/efavirenz 36 1,071 368,000
3 AZT/3TC/nelfinavir 65 339 65,000
4 AZT/3TC/nelfinavir 37 548 14,000
5 AZT/3TC/efavirenz 64 565 200,000
6 3TC/abacavir/efavirenz Over 12 856 N/A
7 3TC/AZT/ritonavir/indinavir Over 12 273 N/A
8 AZT/3TC/efavirenz/nelfinavir 50 760 26,500
9 D4T/3TC/efavirenz 63 503 18,000
10 AZT/3TC/efavirenz 40 586 56,000
11 DDI/D4T/lopinavir/ritonavir Over 12 500 N/A
12 3TC/D4T/saquinavir Over 12 500 N/A
13 AZT/3TC/efavirenz 48 400 900
14 AZT/3TC/efavirenz 52 1,273 67,000
N/A, not available; AZT, azidothymidine; 3TC, lamivudine; D4T, stavudine; DDI, didanosine.
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tent viral reservoirs ex vivo from both PBMCs and resting CD4+ T 
lymphocytes of patients on fully virally suppressive HAART.
Phylogenetic analyses of the HIV-1 Env gp120 genes of IL-7–induced and 
PHA/IL-2–induced viral RNA. To investigate the phylogenetic rela-
tionships of replication-competent viruses and their proviral pool, 
we sequenced in entirety the viral envelope gp120 and obtained 
the genotype of the viruses induced by 
both PHA/IL-2 and IL-7 — as well as 
their corresponding proviruses — from 
4 patients. HIV-1 virion RNA was iso-
lated from coculture supernatants 
(Table 3), and proviral DNA was iso-
lated from the same patients’ PBMCs 
and resting CD4+ T lymphocytes. Ten 
to fifteen clones for each proviral DNA 
or viral RNA sample were sequenced. 
Sequence contaminants were ruled 
out by comparison with common lab-
oratory viral isolates.
The predicted amino acid sequences 
of proviral DNA and viral RNA were 
compared within each patient. Initial 
studies first revealed that potential 
inactivating mutations (i.e., premature 
stop codons and/or frameshifts) were 
present in proviral DNA Env clones, as 
well as in PHA/IL-2–induced viruses. 
In 3 out of 4 patients (patients 1, 3, 
and 4), amino acid sequences of provi-
ral DNAs exhibited high diversity and 
most of the amino acid differences 
were localized in the V1/V2 regions, 
including multiple amino acid substi-
tutions and length polymorphisms. 
On the contrary, extremely high 
homogeneity was observed in the cor-
responding Env gene of virion-encap-
sidated RNA in 11 out of 12 coculture 
supernatants that were positive for HIV-1 p24 antigen. Rare single 
amino acid changes were observed and seemed to be recombinant 
forms of different cell-associated proviruses (data not shown).
In patient 1, IL-7–induced and PHA/IL-2–induced viral geno-
types were quite different from each other. However, within each 
specific cytokine-induced group, viral sequences were found to 
Table 2
HAART-persistent viral outgrowth by cellular activation
Patient  Date of  CD8-depleted PBMC Resting T lymphocyte
no. blood No stimulator PHA/IL-2 IL-7 No stimulator PHA/IL-2 IL-7
1A 1/26/03 NEG POS (2) POS (2) NEG POS (1) POS (4)
 7/16/03 ND ND ND NEG ND POS (5)
2 A 5/20/03 NEG NEG POS (5) ND ND ND
 8/19/03 NEG POS (3) POS (2) ND ND ND
3 B 5/27/03 POS (6) POS (2) POS (5) ND ND ND
 9/23/03 ND ND ND NEG NEG POS (6)
 11/11/03 NEG POS (2) POS (3) ND POS (2) POS (5)
4 A 5/28/03 NEG NEG POS (5) NEG NEG POS (6)
 11/18/03 ND NEG NEG NEG NEG NEG
5 A 3/10/03 NEG NEG NEG NEG NEG NEG
 10/21/03 ND NEG NEG ND POS (2) NEG
6 3/12/03 NEG NEG NEG NEG NEG NEG
7 3/19/03 NEG NEG NEG NEG NEG NEG
8 5/15/03 ND ND ND NEG NEG POS (3)
9 5/22/03 NEG NEG POS (6) ND ND ND
10 A 7/21/03 ND ND ND NEG ND POS (4)
 9/17/03 NEG NEG POS (2) ND ND ND
11 2/3/03 NEG NEG POS (4) ND ND ND
12 1/23/03 NEG NEG NEG ND ND ND
13B 5/21/03 NEG NEG NEG ND ND ND
 9/11/03 NEG NEG NEG ND ND ND
 11/4/03 NEG NEG POS (3) ND ND ND
14 9/30/03 ND ND ND ND NEG NEG
The underlined samples were used for virus genotype sequencing. The numbers in parenthesis indicate 
the week that HIV-1 p24 antigen first became positive. ACocultures were performed on 2 separate occa-
sions on the same patient. BCocultures were performed 3 times for the same patient. POS, positive (HIV-1 
p24 antigen level greater than 30 pg/ml); NEG, negative. ND, not determined.
Table 3
Viral outgrowth (p24 antigen value, pg/ml) during coculture
 Time point of sample collection (wk)
  1 2 3 4 5 6 7 8
Patient 1 (1/26/2003) PBMC/PHA&IL-2 0 259 34,663 81,538 47,206 19,494 19,559 24,956
 PBMC/IL-7 0 226 6,394 32,163 39,519 11,717 22,686 19,766
 Resting T cells/PHA&IL-2 105 20,940 28,441 15,941 20,741 25,606 21,942 27171
 Resting T cell/IL-7 0 0 0 0 30 242 1,430 2,433
Patient 2 (8/19/2003) PBMC/PHA&IL-2 0 0 66 4,939 5,040 4,553 4,602 4,785
 PBMC/IL-7 0 72 2,278 4,826 4,836 4,528 4,878 4,526
Patient 3 (11/11/2003) PBMC/PHA&IL-2 0 4,655 4,836 5,365 5,202 4,448 5,127 5,569
 PBMC/IL-7 0 0 46 4,961 5,205 5,310 5,044 5,539
 Resting T cells/PHA&IL-2 0 4,855 4,774 5,457 5,823 5,205 5,360 5,428
 Resting T cell/IL-7 0 0 0 0 3,933 5,152 5,424 5,238
Patient 4 (5/28/2003) PBMC/IL-7 0 0 0 0  143 3,362 26,000 32,250
 Resting T cell/IL-7 0 0 0 0 0 1,695 39,750 34,750
 Resting T cells/PHA&IL-2A 0 0 5,631 4,100 5,989 4,028 3,218 2,033
The supernatant samples underlined were used for viral gene phylogenetic analysis. Viral RNA was isolated from indicated supernatant samples and PCR 
was performed at least twice. Mixed PCR products were used for TA cloning in order to detect HIV-1 envelope sequence divergence in replication-compe-
tent viral populations. ACoculture was performed on 10/4/2001.
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be homogeneous despite being from of PBMC and resting CD4+ 
T lymphocyte origin. In the full-length 300-AA region V1–V5 of 
HIV-1 gp120 we observed 5 single amino acid changes in 5 separate 
clones (2 in V1/V2, 1 in C2, 1 in V3, and 1 in the C3 region) and 4 
amino acid deletions in another clone (in the C3 region), from a 
total of 8 clones derived from IL-7–induced viral RNA from resting 
CD4+ T lymphocytes. PBMC/IL-7–stimulated viruses contained 2 
single amino acid changes in 2 of the 6 clones (1 in V3 and the other 
in the C3 region). There were 3 single amino acid changes (2 in V1 
and 1 in the C3 region) scattered in 3 of the total 8 clones in resting 
CD4+ T cell/IL-2–stimulated viruses. Similarly, high homogeneity 
was observed in PBMC/IL-7–stimulated viruses for patients 2, 3, 
and 4, resting CD4+ T cell/IL-7–induced viruses for patients 3 and 
4, and PBMC/IL-2–induced viruses for patients 2, 3, and 4. Surpris-
ingly, these initial analyses suggested that certain restricted proviral 
quasispecies had been activated by each specific stimulator.
To further analyze in detail the genetic diversity of the recovered 
viruses by treatment with different cytokines, and to determine the 
potential importance in inducing divergent proviral archives, we 
generated rooted phylogenetic trees using the HIV-1 gp120 V1–V5 
nucleotide sequences for proviruses and induced viruses from each 
of the 4 patients (Figure 1). We evaluated the phylogenetic rela-
tionships among intrapatient sequence sets of PBMC or resting 
CD4+ T lymphocyte proviral DNA and cell-free viral RNA induced 
by IL-7 or PHA/IL-2. Of note, the laboratory viral strain HXB2 seg-
regated distantly from all patients’ sequences.
The phylogenetic tree for patient 1 reveals an interesting intra-
patient sequence relationship. There are 2 primary branches, as 
shown in Figure 1A. The top branch represents viral RNA from 
IL-7–stimulated cocultures, and the bottom branch illustrates viral 
RNA from PHA/IL-2–stimulated cocultures. Proviral DNAs from 
PBMCs and resting CD4+ T lymphocytes were detected on both 
branches. These data indicated that IL-7 and PHA/IL-2 induced 
the replication of distinct viruses that belonged to different 
subpopulations that were contained in the same proviral pool. Of 
interest, a similar phenomenon was observed for patient 2, as shown 
in Figure 1B. In patients 1 and 3 (Figure 1, A and C), IL-7 induced 
the replication of very similar HIV-1 isolates (i.e., segregated in the 
same branch of the phylogenetic tree) regardless of whether PBMCs 
or pure resting CD4+ T lymphocytes were stimulated, showing a 
highly provirus-specific effect. Interestingly, in patient 3, IL-7 and 
PHA/IL-2 induced the growth of 2 distinct viruses, on separate 
branches, solely from resting CD4+ T lymphocytes. This suggests 
a selective effect on a true latent HIV-1 reservoir not contaminated 
by the presence of activated CD4+ T lymphocytes in PBMCs, known 
to produce low levels of HIV-1 replication. We were able to show 
that the separation of these 2 distinct viruses in 2 separate branches 
could be found, in patient 3, even when the entire full-length HIV-1 
genome was sequenced and analyzed (data not shown). In patient 
3, envelope sequences also derived from full-length viral sequenc-
ing fit into the subbranches of the tree based on PHA/IL-2 versus 
IL-7 treatment (Figure 1C). Similarly, for patient 4, viral popula-
tions were again clustered tightly in quite separate subbranches, as 
shown in Figure 1D. Finally, intrastimulus viral quasispecies were 
also analyzed. IL-7–induced virus showed high homogeneity in 3 
out of 4 patients, while much more diversity was observed in PHA/
IL-2 virus populations (data not shown).
The segregation of these HIV-1 viral populations induced by 
diverse stimulators highlights that proviral reactivation by differ-
ent cytokines may be from differing proviral quasispecies exist-
ing in the same or different latently infected CD4+ T lymphocyte 
subpopulations. These results suggest that more than one stimu-
lator might be needed, in combination, to purge or deplete HIV-1 
reservoirs in a more efficient and complete manner.
IL-7–mediated viral replication is in part dependent on activation of rest-
ing CD4+ T lymphocytes. Cytokine treatment can alter the activation 
state of the host cells and thus change patterns of viral replication. 
Our findings that IL-7 induced expression of latent virus effec-
tively from patients’ PBMCs and resting CD4+ T lymphocytes sug-
gested that this cytokine activated the latently infected peripheral 
resting CD4+ T lymphocytes harboring HIV-1 proviral DNA. The 
expression of various activation and proliferation markers, includ-
ing CD25, CD69, HLA-DR, and Ki-67, were then assessed. Resting 
CD4+ T lymphocytes were purified from healthy donors’ peripheral 
blood and treated with IL-7 alone (20 ng/ml) for 14 days or PHA 
(5 μg/ml for 48 hours) plus IL-2 (20 ng/ml) for 3 days. As shown 
in Figure 2A, we observed an increased number of cells expressing 
the activation marker CD25 in IL-7–treated resting T cell popula-
tions, which was associated with an increase of the proliferation 
marker Ki-67, but not with an increase in HLA-DR or CD69 (data 
not shown). A high level of CD25 expression (36.2%) was observed 
on day 1 and increased at the following time points (71.4% on day 7 
after treatment), as compared with untreated cells (data not shown). 
Ki-67 expression peaked on day 7 (13%) and was followed by a rapid 
decline (data not shown). Intracellular Ki-67 staining demonstrat-
ed the proliferation of IL-7–treated resting CD4+ T lymphocytes, 
in agreement with previous studies (31–36). Figure 2B illustrates 
the cell activation efficiency when treated with PHA and then IL-2. 
These results suggest that the partial activation and proliferation of 
the resting T lymphocyte population treated with IL-7 may contrib-
ute to the induction of HIV-1 replication out of latency.
To further define the extent of cellular activation, we tested the 
effect of IL-7 on inducing cell-cycle progression. Highly purified 
resting CD4+ T lymphocytes were cultured in media alone or in the 
presence of IL-7 for 7 days. As shown in Figure 2C, an increase in 
cellular RNA was observed on day 3 after treatment and, on day 7, 
17% of the cells progressed into the S and G2/M phase of the cell 
cycle (data not shown). These data lead us to further suggest that 
IL-7–induced cellular proviral expression could be partially based on 
its effect on cell activation and cell-cycle progression.
To test whether IL-7–induced resting T lymphocyte activation 
was an incidental cross-reactive effect of autocrine-mediated 
release of secondary cytokines from the IL-7–stimulated resting 
CD4+ T lymphocytes, we used a proteomics microarray in cocul-
ture supernatants of both IL-7–treated and untreated resting T 
lymphocytes to test for the presence of 42 cytokines. We did not 
detect any significant difference in endogenous cytokine release 
(data not shown). These results suggest a potential direct effect of 
IL-7 in inducing resting CD4+ T lymphocyte activation without 
intermediate interaction of other released cytokine(s).
Infectivity of PHA/IL-2–induced and IL-7–induced viruses. Next, 
we examined the infectivity and replication-competence of both 
PHA/IL-2–induced and IL-7–induced viruses. The HIV-1NL4-3 iso-
late was used as a positive control. The viruses were normalized 
by HIV-1 p24 antigen levels to an input concentration of 5 ng/ml 
per 106 cells. The kinetics of HIV-1 replication was measured by 
HIV-1 p24 antigen detection in triplicate culture supernatants. As 
shown in Table 4, both PHA/IL-2–induced and IL-7–induced viri-
ons have comparable infectivity with the laboratory strain NL4-3. 
These data indicate that the cytokine-induced viruses are fully 
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Figure 1
Phylogenetic analyses of HIV-1 
envelope gene sequences of pro-
viral DNA and cytokine-induced 
virion RNA from the same cell pop-
ulations. The full-length of gp120 
V1 to V5 regions were cloned and 
sequenced directly from proviral 
DNA of PBMCs and purified, rest-
ing CD4+ T lymphocytes, and IL-7 
or PHA/IL-2–induced virion RNA 
for 4 patients (numbers 1–4, A–D). 
Proviral DNA sequences are pre-
sented by black stars (open stars 
for those strains from PBMC and 
filled for those of resting CD4+ T 
lymphocytes). IL-7–induced viral 
RNA sequences are indicated by 
blue squares (open squares for 
PBMC and IL-7–induced and filled 
squares for resting CD4+ T lympho-
cyte and IL–induced). PHA/IL-2– 
induced viral RNA sequences 
are indicated by red circles (open 
circles for those induced by PBMC 
with PHA/IL-2 and filled circles for 
those induced by resting CD4+ 
T- lymphocyte with PHA/IL-2). 
Growth of patient 4’s virus from 
PBMCs with PHA/IL-2 was from 
10/04/2001. All sequences are 
shown with HXB2 (GenBank 
accession no. K03455) as the ref-
erence outgroup. Branch lengths 
are drawn in proportion to the 
number of nucleotide substitutions 
per site, and bootstrap probabili-
ties (1,000 iterations) exceeding 
70% for each node are noted.
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Figure 2
Stimulatory patterns of resting CD4+ T lymphocytes by IL-7. (A and B) Detection of cell activation markers in IL-7–treated or PHA/IL-2–treated 
human resting CD4+ T lymphocytes. Freshly isolated resting CD4+ T lymphocytes stimulated with IL-7 or PHA/IL-2 were stained with FITC-con-
jugated anti–KI-67, anti–HLA-DR, and PE-conjugated anti-CD25. Three independent experiments were performed, of which one representative 
is illustrated. Gm, geometric mean; CV, coefficient of variance. (C) Effects of IL-7 on the cell cycle of human peripheral blood resting CD4+ T 
lymphocytes. IL-7 alone or PHA/IL-2–stimulated, initially resting CD4+ T lymphocytes are shown with the cell-cycle status indicated in each quad-
rant. DNA is depicted on the vertical axis and RNA is shown on the horizontal axis. Positions indicating stages in the cell cycle are illustrated in 
the third panel. The cell cultures either alone or in the presence of IL-7 were continued for a full 7 days. PHA/IL-2–stimulated cells were treated 
with PHA (5 μg/ml) for 48 hours and then IL-2 (10 ng/ml) for 3 days.
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replication-competent and capable of perpetuating the spread of 
HIV-1 to uninfected cells.
IL-7 and HIV-1 long terminal repeat transactivation. Finally, to eval-
uate and precisely isolate the potential differential effects of the 
stimulatory regimens on HIV-1 long terminal repeat–mediated 
(HIV-1 LTR–mediated) transcription, we performed gene reporter 
assays. These assays demonstrated that IL-7, at 6 hours after addi-
tion, induced HIV-1 LTR activity by only 2-fold at a concentration 
of 100 ng/ml, while at lower concentrations (i.e., 10–20 ng/ml), 
IL-7 demonstrated no effect. IL-2 alone (10 ng/ml), 6 hours after 
addition, did not have any effect on HIV-1 LTR activity. Both 
PMA and PHA (10 ng/ml), 6 hours after addition, significantly 
induced HIV-1 LTR activity by approximately 25-fold (data not 
shown). These results suggest that, at least in this specific HIV-1 
LTR transactivation assay, IL-7 exerts only a modest effect on LTR-
directed transcription, and thus this may not represent the molecu-
lar pathway involved with more robust stimulation of archival pro-
viruses in the PBMCs of patients on virally suppressive HAART.
Of note, differences in specific induction of select proviruses 
by divergent cytokines could be related to the existence of diverse 
proviral quasispecies in distinct subpopulations of resting CD4+ T 
lymphocytes, such as CD4+/CD45RA+ naive and CD4+/CD45RO+ 
memory T lymphocytes, or to regulation of viral expression by 
specific cytokines, possibly through their effects on viral tran-
scription. As such, we sequenced the LTRs of replication-compe-
tent viruses induced by IL-7 and PHA/IL-2 in certain individuals. 
Nonetheless, there were no specific nucleotide sequence differ-
ences in the LTR U3 regions from paired cytokine-induced viruses 
(i.e., PHA/IL-2–induced versus IL-7–induced) in the 2 patients 
analyzed (data not shown).
Discussion
The addition of T cell–activating agents to potent antiretroviral 
therapy has been proposed as a possible strategy to purge cellular 
reservoirs in long-lived, HIV-1–infected quiescent CD4+ T lympho-
cytes. IL-2 administration is one of the most extensively studied 
immune-based therapies in HIV-1–infected individuals (7). IL-2 in 
combination with HAART has led to CD4+ T lymphocyte expan-
sion, although it had modest effects on purging the HIV-1 reser-
voir either alone or in combination with OKT-3. IL-7 has been 
proposed as a possible supplement to HAART (28), not only for 
its immunomodulatory properties and its crucial role in T cell 
homeostasis, but also to deplete HIV-1 reservoirs by stimulating 
the pool of latently infected cells.
In the present study, we investigated the effects of IL-7 and PHA/
IL-2 on HIV-1 replication in CD8+ T cell/monocyte–depleted PBMCs 
and resting CD4+ T lymphocytes freshly isolated from HIV-1–infect-
ed individuals on virally suppressive HAART and with plasma HIV-1 
RNA levels lower than 50 copies/ml. We demonstrated that IL-7 is 
more effective than IL-2 in enhancing HIV-1 proviral reactivation, 
not only from CD8+ T cell/monocyte–depleted PBMCs but also 
from resting CD4+ T lymphocytes. IL-7 was able to induce HIV-1 
replication in 56% of CD8+ T cell/monocyte–depleted PBMCs and in 
45.5% of pure populations of resting CD4+ T lymphocyte cocultures. 
Importantly, PHA/IL-2 stimulation induced HIV-1 replication in 
only 22% and 27.3% of CD8+ T cell/monocyte–depleted PBMCs and 
resting CD4+ T lymphocyte cocultures, respectively. Moreover, in 6 
patients when IL-7 was compared with IL-2 alone, we found that 
the latter did not induce HIV-1 replication in any of the coculture 
assays, while 3 out of 5 cocultures treated with IL-7 were positive for 
viral outgrowth (data not shown).
In a previous study in the pre-HAART era, IL-7 was shown to 
upregulate HIV-1 replication from PBMCs of HIV-1–infected indi-
viduals ex vivo, although these subjects were not on HAART, and 
thus the noise of high levels of viral load and continuous viral rep-
lication prevented further analysis regarding the possible effects on 
true HIV-1 latency (25). In our study, the effects of IL-7 on HIV-1 
replication were tested in both CD8+ T cell/monocyte–depleted 
PBMCs and pure populations of resting CD4+ T lymphocytes, with 
complementary results. Moreover, our present data indicate that 
IL-7 had a direct effect on resting CD4+ T lymphocyte–associated 
viral outgrowth. This rules out the possibility that contaminat-
ing cells in the CD8+ T cell/monocyte–depleted PBMC cocultures 
may have interfered with the induction of HIV-1 replication, either 
directly or through the release of cytokines or chemokines. Fur-
thermore, potentially interfering secondary cytokines were not 
detected in IL-7–treated resting CD4+ T cell coculture superna-
tants, via a proteomics approach. Thus, these results strongly sug-
gest that IL-7 alone is more efficient than PHA/IL-2 in inducing 
HIV-1 replication directly from latently infected cells of HIV-1–
infected subjects on HAART. In future studies, it will be interest-
ing and possibly important to combine IL-7 with other cytokines 
including, but not limited to, IL-2.
We hypothesized that IL-7 and PHA/IL-2 stimulation might induce 
the replication of different viral strains. As such, the HIV-1 envelope 
gp120 V1–V5 region was sequenced and analyzed. Interestingly, 
the phylogenetic trees revealed that in patients 1 and 2 there were 
2 primary branches showing distinct segregation of sequences with 
regard to PHA/IL-2–induced and IL-7–induced viruses (Figure 1, 
A and B). Patient 3 revealed distinct PHA/IL-2–induced versus 
IL-7–induced virions from solely resting CD4+ T lymphocytes 
(Figure 1C). In patient 4, 2 viral populations were also clustered 
tightly in separate sub-branches (Figure 1D). Cytokine-induced 
replication-competent viruses were contained in the corresponding 
Table 4
Comparison of the replication competence of viruses
 HIV-1 p24 antigen expression
HIV-1 viral input Day 7 (after infection) Day 14 (after infection)
 IL-7 virus PHA/IL-2 virus NL4-3 IL-7 virus PHA/IL-2 virus NL4-3
1:1 (5 ng/ml of HIV-1 p24) +++ ++++ ++++ ++++ ++++ ++++
1:4 + ++++ ++++ ++++ ++++ ++++
1:16 – ++ + ++++ ++++ +++
–, less than 30 pg/ml; +, 30–60 pg/ml; ++, 60–120 pg/ml; +++, 120–240 pg/ml; ++++, more than 240 pg/ml. The level of virus p24 antigen was below 30  
pg/ml for all samples on day 0.
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proviral pool of PBMCs and/or pure resting CD4+ T lympho-
cytes. These results strongly indicated that different cytokines had 
induced divergent proviral DNA expression from the CD4+ T lym-
phocyte proviral archive. It remains a formally possible hypothesis 
that the existence of diverse proviral quasispecies may occur in dis-
tinct subpopulations of resting CD4+ T lymphocytes, such as CD4+/
CD45RA+ naive and CD4+/CD45RO+ memory T lymphocytes. In 
addition, regulation of viral expression by specific cytokines, possi-
bly through their effects on viral transcription or at other sites of the 
lentiviral life cycle, may have led to viral strain–specific induction.
Resting CD4+ T lymphocytes are considered a major HIV-1 res-
ervoir (1). Thus, we investigated whether IL-7 had an effect on the 
activation or proliferation of these cells, which might be involved 
in the induction of HIV-1 from latency. We observed an increased 
expression of CD25 in the IL-7–treated resting CD4+ T lymphocyte 
population in accordance with previous results, which further dem-
onstrated that CD4+/CD25+ T cells actively produce virus in vitro 
(37). The expression of T cell activation markers CD69 and HLA-DR 
was not modified by IL-7. Moreover, IL-7 induced an increase of the 
proliferation marker Ki-67 in resting CD4+ T lymphocytes, as well 
as their progression into S and G2/M phases of the cell cycle.
In the interest of evaluating the potential use of IL-7 in humans, 
in vivo studies in a SCID-hu mouse model (28) and in macaques 
(31) have been performed, and the immunological and virological 
effects of IL-7 were assessed. In SIV-infected monkeys, a remarkable 
increase in CD4+ T cells, particularly CD4+ and CD8+ naive T cells, 
was demonstrated. Furthermore, the absolute number of CD4+ 
HLA-DR+ cells was augmented and correlated with an increase of 
the absolute number of Ki-67–positive cells (31). Surprisingly, IL-7 
did not alter the plasma viral load levels, in accordance with a pre-
vious study by Fry et al. (38), in which antiretroviral therapy was 
administered. On the other hand, in the SCID-hu mouse model, 
IL-7 effectively stimulated the pool of latently HIV-1 infected cells 
while having minimal effects on T cell phenotype (28). Of note, 
IL-7 has been used in combination with an HIV-1–specific immu-
notoxin, with some success, to activate and deplete viral residual 
disease, also in SCID-hu mice (39).
The present studies provide direct evidence that exogenous 
IL-7 upregulated the expression of HIV-1 in latently infected cells 
from HIV-1–infected individuals on suppressive HAART, more 
effectively than did PHA/IL-2 or IL-2 alone. In previous studies, 
1 cytokine alone rarely had robust effects on activating proviruses 
from latency (30). Of importance, different viral quasispecies from 
the same cellular latency pool were induced. The present findings 
suggest that cytokine combinations might be required in addi-
tion to HAART to stimulate diverse HIV-1 proviral quasispecies 
from latency. Not only is IL-7 alone more potent than PHA/IL-2, 
but it is important to point out that PHA cannot be used in a 
regimen for humans. Intensification therapy added to HAART, 
to attempt to inhibit viral spread of stimulated virions, and the 
immunomodulatory effects of IL-2 and IL-7, should now be taken 
into consideration (40), as they may act synergistically in control-
ling cytokine-induced reactivation of HIV-1. Further studies are 
needed to now rationally design clinical protocols to deplete or 
purge latent HIV-1 residual disease with these agents (41).
Methods
Study subjects. Fourteen HIV-1–infected individuals on stable virally sup-
pressive HAART were enrolled in this study. All patients had at least 2 
ultrasensitive RT-PCR results demonstrating plasma viral RNA levels below 
50 copies/ml, and had undetectable plasma viral loads for at least a year 
prior to the study. Blood samples were obtained by peripheral phlebotomy. 
Each subject signed a consent form that was approved by the Institutional 
Review Board of Thomas Jefferson University.
Resting CD4+ T lymphocyte isolation. Resting CD4+ T lymphocytes were iso-
lated using a Miltenyi automated cell-isolation device (autoMACS, Miltenyi 
cell-separation device; Biotech Inc.). Patients’ PBMCs were separated from 
blood plasma by discontinuous Ficoll-Hypaque (Sigma-Aldrich) centrifuga-
tion. PBMCs were depleted of CD8+, CD14+, CD19+, CD56+, CD36+, CD123+, 
CD235a+, CD16+, and anti-TCRγ/δ+ cells by direct immunomagnetic label-
ing, using antibodies against their respective surface markers (Miltenyi 
Inc.). The negative fraction was then depleted of CD25+ and HLA-DR+ 
cells by direct immunomagnetic conjugation and further separation. The 
negative fraction consisted of CD4+, HLA-DR–, and CD-25– resting T lym-
phocytes (resting CD4+ T lymphocytes).
HIV-1–seronegative donors’ PBMCs were depleted of CD8+ T lympho-
cytes by binding with magnetic beads conjugated with anti-CD8 antibody 
(CD8 Dynabeads from Dynal). This process decreases the fraction of CD8+ 
T lymphocytes in the PBMCs from approximately 20–30% to 3–5%, as 
analyzed by flow cytometry (42). Macrophages and their precursors were 
depleted from PBMCs by incubating the samples overnight to allow these 
cells to attach to the plastic plates. The remaining PBLs were then stimu-
lated with 5 μg of PHA per milliliter (Sigma-Aldrich) and 10 ng/ml of IL-2 
(Invitrogen Corp.).
Cell culture conditions and coculture assays. Patients’ PBMCs or isolated rest-
ing CD4+ T lymphocytes were cultured in RPMI-1640 medium with 10% 
FCS and penicillin plus streptomycin at 37°C for 8 to 10 weeks in the pres-
ence of 10 or 20 ng/ml of IL-7 (R&D Systems Inc.), as described previously 
(25, 28, 39), or prestimulated with 5 μg/ml of PHA and then 5–10 ng/ml of 
IL-2 (2, 30). Once a week, half the medium was replaced with fresh medium 
and half the cells were replaced with fresh PBMC from HIV-1 seronegative 
subjects. HIV-1 p24 antigen was measured in the supernatants by an ELISA 
(Dupont). Positive cultures were defined as those demonstrating at least 
30 pg/ml of HIV-1 p24 antigen in the culture supernatant. All procedures 
were performed under biosafety level-3 conditions to minimize the pos-
sibility of cross-contamination.
Flow cytometry for surface and intracellular cell markers. To assess the purity 
of the cell populations and the expression levels of cell activation markers 
after cytokine treatment, we stained 5 × 105 cells with monoclonal antibod-
ies to specific cell surface markers (BD Biosciences — Pharmingen) against 
HLA-DR (also known as major histocompatibility complex II), CD25 (IL-2 
α receptor; i.e., surface activation marker), CD14 (macrophage marker), 
CD3 (T lymphocyte marker), CD69 (an early marker of T cell activation), 
or intracellular marker against Ki-67 (proliferation marker). For staining, 
anti–HLA-DR and Ki-67 monoclonal antibodies were conjugated directly 
to FITC; anti-CD25 was conjugated directly to PE, and anti-CD69 was 
conjugated directly to peridinin chlorophyll protein. The staining was per-
formed on ice for 30 minutes, then it was subsequently washed 3 times 
with phosphate-buffered saline (1×) and fixed in 2% paraformaldehyde. 
Intracellular Ki-67 staining was performed by initially fixing and permea-
bilizing the lymphocytes with FACS Cytofix/Cytoperm solution (BD), fol-
lowed by intracellular staining with the Ki-67-FITC antibody. Data were 
accumulated on a BD FACSCalibur flow cytometer and subsequently ana-
lyzed with the Flowjo Software Program (TreeStar Inc.).
Cell-cycle analyses. Cells (5 × 105 under each set of conditions) were stained 
for DNA and RNA content with 7-amino-actinomycin D and pyronin Y, 
respectively (43). Briefly, cells were suspended in 475 μl of nucleic acid 
staining solution (0.15 M NaCl in 0.1 M phosphate-citrate buffer contain-
ing 5 mM sodium EDTA (Sigma-Aldrich) and 0.5% BSA (Sigma-Aldrich), 
pH 6.0 containing 0.03% saponin (Sigma-Aldrich). 7-amino-actinomycin D 
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(Sigma-Aldrich) was added at a final concentration of 20 μM. Cells were 
incubated for 30 minutes and then cooled on ice for 10 minutes. Then, 
pyronin Y (Sigma-Aldrich) was added at a final concentration of 5 μM, 
cells were incubated for additional 10 minutes on ice, and finally fixed in 
2% paraformaldehyde until analysis.
HIV-1 Env gp120 and LTR U3 genotype characterizations. The sequences of the 
V1 to V5 region of HIV-1 Env gp120 of both proviral DNA (isolated from 
CD8-depleted PBMCs and purified resting CD4+ T lymphocyte) and virion-
encapsidated RNA (as cell-free virus outgrowth in coculture supernatants) 
were determined by nested PCR assay. Two different time-point superna-
tant samples were used for viral RNA isolation. Nucleic acid isolation, cDNA 
synthesis, and PCR amplification of DNA and cDNA were performed as 
described previously (44). The viral RNA was reverse-transcribed with the 
Superscript preamplification system (Invitrogen Corp.) with an antisense 
external primer R02 (5′-TAGTGCTTCCTGCTGCTCCCAAGAACCC-3′), 
and the cDNA underwent nested PCR. The outer primer pair for the V1 to 
V5 region of HIV-1 envelope gp120 was F02 (5′-AGAAAGAGCAGAAGA-
CAGTGGCAATGA-3′) and R02 (sequence above), and the inner primer pair 
was F01 (5′-ACACATGCCTGTGTACCCCACGAC-3′) and R01 (5′-GTGCTA-
CACCTAATGGTTCAA-3′). The amplified DNAs were isolated from agarose 
gels, cloned into the pGEM-T easy vector (Promega Corp.), and transformed 
into competent DH5α cells (Invitrogen Corp.). Ten to 15 clones were selected 
and sequenced with an automated sequencer (Prism model 377, with XL 
upgrade, PerkinElmer Applied Biosystems) The sequences were analyzed 
using Lasergene sequence analysis software obtained from DNASTAR Inc. 
Sequence contaminants were ruled out by comparison of obtained sequenc-
es with common laboratory viral isolates. The sequences have been submit-
ted to GenBank (accession numbers AY549051 to AY549086 [patient 1], 
AY549124 to AY549147 and  AY553649 to AY553650 [patient 2], AY576490 
to AY576525 [patient 3], and AY549087 to AY5494123 [patient 4]). Perfectly 
matched DNA-based sequences within each patient grouping were not reiter-
ated in the submission. In addition, the full-length viral genomes of patient 3 
were sequenced from PMCSs and resting CD4+ T cell supernatants that were 
stimulated by PHA/IL-2 and IL-7, as described previously (45).
To investigate the possible LTR sequence divergence of diverse cytokine-
induced replication-competent viruses, which could regulate viral tran-
scription, viral RNA samples isolated from paired IL-7 and PHA/IL-2 
coculture supernatants were employed and the 3′ LTR region was ampli-
fied and sequenced. The outer primer set was U3F1 (5′-CAGTCACACCT-
CAGGTACC-3′) and U3R1 (5′-TGCTAGAGATTTTCCACACTG-3′), and 
the inner primer pair was U3F2 (5′-AGACCAATGACTTACAAGG-3′) and 
U3R2 (5′-TGAGGGATCTCTAGTTACCAGAGT-3′).
Phylogenetic analysis. Sequence electrophoregram data were analyzed 
using Seqman (DNASTAR Inc.). Multiple alignments were performed 
with CLUSTALW version 1.8 (46). Intrapatient viral envelope sequences 
were compared with each other and to the control sequence (HXB2), using 
Lasergene sequence analysis software obtained from DNASTAR Inc. to 
exclude any possibility of sample contamination. Dendrograms were cre-
ated by the neighbor-joining method of Saitou and Nei (47). Bootstrap 
analysis consisting of 1,000 replicates was performed with the CLUSTALW 
program. Bootstrap values of 70% or higher were considered significant.
Infectivity assays. PHA-stimulated PBMCs from HIV-1–seronegative donors 
(after depletion of CD8+ T lymphocytes and monocyte/macrophages) were 
infected by viruses induced by IL-7 or PHA/IL-2, as well as the laboratory 
viral strain NL4-3, for 4–6 hours at 37°C. The input viral concentrations 
were normalized by HIV-1 p24 antigen equivalents (5 ng/ml per 1 × 106 
cells as the highest dose). Residual input virus was removed and cells 
(2 × 106) were then cultured, in triplicate, in 2 ml of RPMI-1640 medium 
plus 10% FCS for 14 days. The supernatants were collected for the detec-
tion of HIV-1 p24 antigen on days 0, 7, and 14 of culture via ELISA.
Cytokine measurements. To assess whether IL-7–treated, resting CD4+ T 
lymphocytes released secondary cytokine(s) that subsequently acted on 
CD4+ T lymphocyte activation, we cultured purified resting CD4+ T lym-
phocytes either alone or with IL-7 in parallel for 7 days. The cell purity was 
greater than 99%. The levels of 42 human cytokines (including ENA-78, 
GCSF, GM-CSF, GRO, GRO-a, I-309, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IFN-γ, MCP-1, MCP-2, MCP-3, 
MCSF, MDC, MIG, MIP-1δ, RANTES, SCF, SDF-1, TARC, TGF-β1, TNF-α, 
TNF-β, EGF, IGF-1, Ang, OSM, Tpo, VEGF, and PDGF B) in culture super-
natants were evaluated using the Human Cytokine Array III kit (RayBio-
tech Inc.), according to the protocol provided by the manufacturer.
HIV-1 LTR transactivation and gene-reporter assays. The effects of IL-7 on 
transactivation of the HIV-1 LTR were analyzed by means of the 1G5 cell 
line, a Jurkat T cell line that is stably transfected with an HIV-1 LTR–
luciferase construct (NIH AIDS Research and Reference Reagent Program). 
1G5 cells (2 × 106 cells/ml maintained in RPMI-1640 media supplemented 
with 10% fetal bovine serum) were treated with various concentrations of 
IL-7 (10–100 ng/ml). Cells were collected at different time points (6, 24, 
and 48 hours after addition of IL-7), lysed in 100 μl of reporter lysis buf-
fer (BD Biosciences — Pharmingen), and assayed for luciferase activity by 
using commercially available reagents (BD Biosciences — Pharmingen) with 
a FB12 Luminometer (Zylux Corp.). The effects of PHA (10 ng/ml), PMA 
(10 ng/ml), and IL-2 (10 ng/ml) were also analyzed separately in these assays.
Statistical analyses. The significance of differences in the efficiency of viral 
growth from latently infected cells stimulated by IL-7 and PHA/IL-2 was 
analyzed using the χ2 test. P values of less than 0.05 were considered to be 
statistically significant.
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